Bergen, 31 July 2007; NorDiag said in a stock exchange release February 21 that the Company had an case report accepted for publication in a leading European medical journal presenting the usefulness of GenefecTM. The Company has today been informed that the report will be published in the august issue of European Journal of Gastroentology & Hepatology and is today published at www.eurojgh.com.

The test can identify early stages of colorectal cancer long before alternative methods, and the `case report` is reporting on such an incident where the patient was recovered after simple surgery.

Abstract of the article can be found at www.eurojgh.com

The report demonstrates how useful regularly testing with a genetic marker as GenefecTM can be for members of risk groups of colorectal cancer. One million people are affected yearly of bowel cancer, and despite improvements in diagnostics and treatment, not more than half of the patients survive. Survival rates increases with early detection, and costs of treatment are reduced. NorDiag`s Genefec test identifies a substantial part of the early stages to colorectal cancer.

Contact person: CEO Mårten Wigstøl, mob. + 47 911 657 75

About NorDiag ASA:
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed at Oslo Stock Exchange with the ticker NORD. www.nordiag.no